Drug Registration and Acceptance

Drug Name

Exact

Active Ingredient

Acceptance No.

Manufacturers

Acceptance Date

Status Date

Classification

Review Status

Drug Type

Submission

Evaluation Conclusion

ATC Category

Special Approval Varieties

Task Type

Major Special Varieties

Sequence No.

Stock Code

Visualized Analysis Export Evaluation Conclusion Evaluation Progress

Acceptance No.	Drug Name	Active Ingredient	Dosage Form	Classification	Submission	Acceptance Date	Manufacturers	Manufacturers	Review Status	Status Date	View
JYHZ2100505	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	License Renew	2021-03-12					view
JYHZ2100504	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	License Renew	2021-03-12					view
JYHZ2100503	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	License Renew	2021-03-12					view
JYHZ2100502	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	License Renew	2021-03-12					view
JYHZ2100501	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	License Renew	2021-03-12					view
JYHZ2100500	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	License Renew	2021-03-12					view
JYHB2200630	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	Supplementary Application	2022-11-15		Boehringer Ingelheim International GmbH			view
JYHB2200629	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	Supplementary Application	2022-11-15		Boehringer Ingelheim International GmbH			view
JYHB2200628	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	Supplementary Application	2022-11-15		Boehringer Ingelheim International GmbH			view
JYHB2200627	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	Supplementary Application	2022-11-15		Boehringer Ingelheim International GmbH			view
JYHB2200626	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	Supplementary Application	2022-11-15		Boehringer Ingelheim International GmbH			view
JYHB2200625	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	Supplementary Application	2022-11-15		Boehringer Ingelheim International GmbH			view
JYHB2200098	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	Supplementary Application	2022-02-25		Boehringer Ingelheim International GmbH			view
JYHB2200097	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	Supplementary Application	2022-02-25		Boehringer Ingelheim International GmbH			view
JYHB2200096	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	Supplementary Application	2022-02-25		Boehringer Ingelheim International GmbH			view
JYHB2200095	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	Supplementary Application	2022-02-25		Boehringer Ingelheim International GmbH			view
JYHB2000508	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	Supplementary Application	2020-04-24	勃林格殷格翰（中国）投资有限公司	Boehringer Ingelheim (China) Investment Co Ltd	Certificate Issued	2020-06-04	view
JYHB2000507	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	Supplementary Application	2020-04-24	勃林格殷格翰（中国）投资有限公司	Boehringer Ingelheim (China) Investment Co Ltd	Certificate Issued	2020-06-04	view
JYHB2000506	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	Supplementary Application	2020-04-28	勃林格殷格翰（中国）投资有限公司	Boehringer Ingelheim (China) Investment Co Ltd	Certificate Issued	2020-06-04	view
JYHB2000505	马来酸阿法替尼片	Afatinib Dimaleate	Tablet	Chemical Drugs	Supplementary Application	2020-04-28	勃林格殷格翰（中国）投资有限公司	Boehringer Ingelheim (China) Investment Co Ltd	Certificate Issued	2020-06-04	view